相关实验视频

Updated: Jul 16, 2025

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

Published on: October 14, 2015

BRCA1表达,与临床病理特征的相关性,以及对高度血清性卵巢癌中新辅助化疗的反应

Akkamahadevi Patil¹, Sharada Patil², C E Anupama²

¹Department of Histopathology, Kidwai Memorial Institute of Oncology, Bangalore, India.

The journal of obstetrics and gynaecology research

|September 22, 2023

概括

BRCA1/ID4比率可以预测高度血清性卵巢癌 (HG-SOC) 中的新辅助疗法反应. 这一比率反映了BRCA1通路活性,显示了在HG-SOC患者中引导治疗决策的潜力.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

高度血清性卵巢癌 (HG-SOC) 经常涉及BRCA1突变,但非突变性BRCA通路失活机制尚不清楚.
了解这些机制对于确定替代治疗点和预测治疗反应至关重要.

研究的目的:

通过评估HG-SOC瘤中的BRCA1表达及其抑制剂ID4来评估BRCA1无活化.
研究BRCA1/ID4比率与临床病理特征和对新辅助化疗 (NACT) 的反应的关联.

主要方法:

免疫组织化学和qPCR用于评估119个HG-SOC瘤 (初级和NACT治疗) 的BRCA1和ID4表达.
评估了组织学模式 (SET),瘤透淋巴细胞 (sTILs) 和化疗反应评分 (CRS).
分析了BRCA1/ID4比率与包括CRS在内的临床病理特征之间的相关性.

主要成果:

在初级 (12%) 和NACT治疗的 (19%) HG-SOC中,BRCA1蛋白表达很低.
高的BRCA1mRNA表达与特定的组织学模式,增加的STILs和更高的线粒分裂相关.
在初级和NACT治疗的瘤中,较高的BRCA1/ID4比率与高的sTIL密度有关.

结论:

BRCA1/ID4比率显示出在预测HG-SOC中新辅助疗法反应方面具有潜在的实用性.
需要在更大的队列中进一步验证长期结果数据,以证实这些发现.

关键词:

在BRCA1的功能障碍.在 HG-SOC 中.在ID4 ID4 ID4 ID4 ID4 ID4 纳克特的回应是NACT的回应.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...